ONOCOR

ONOCOR Vascular is a clinical-stage medical device company addressing a critical complication in the rapidly growing field of catheter-based structural heart interventions: the need to retrieve suboptimal or embolized implants. The company's lead product, the ONO transcatheter retrieval system, is designed to safely and reliably receive, align, compress, and remove devices like left atrial appendage occlusion (LAAO) plugs through a minimally invasive approach. With a first-in-human case successfully published in 2024, ONOCOR is positioned to capitalize on the expansion of transcatheter therapies by offering a specialized tool that could improve procedural safety and expand patient eligibility. The company is led by a team of physician co-founders and an experienced CEO, operating as a private, pre-revenue entity.

Catheter-based retrieval system designed to percutaneously receive, align, compress, and remove embolized or malfunctioning cardiovascular implants.

No dedicated, FDA-cleared retrieval system for structural heart devices is widely commercialized, making ONOCOR a potential first-mover. However, physicians currently use off-label tools like snares and bioptomes, representing the entrenched, low-cost competition. Device manufacturers may also design future implants for easier retrieval.